Clin2
NCT06961201Possibly a fitNot yet recruiting

Appetite medicine study for lung cancer with weight loss

Extensive-stage Small Cell Lung Cancer (ES-SCLC)The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy

Treatments studied

Part of Cancer, Lungs & breathing clinical trials.

This trial tests a new appetite-boosting medicine (nano-crystalline megestrol acetate) added to standard chemotherapy for people with advanced small cell lung cancer who are losing weight. It aims to see if it helps with weight, strength, and treatment response.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
94 people
Ages
18 years to 85 years
Study type
Interventional

Who can take part

  • You have been diagnosed with extensive-stage small cell lung cancer (cancer that has spread beyond one lung).
  • You have not had chemotherapy for this specific cancer before (unless it was more than 6 months ago).
  • You have cancer-related weight loss or are at risk of it (pre-cachexia or cachexia).
  • You are not taking any other appetite-boosting medications like steroids or hormone pills.
  • You can swallow and digest food normally without needing a feeding tube.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06909383Not yet recruiting· Phase 2
A drug for appetite and weight loss in advanced lung cancer

This trial tests a medicine called nanocrystalline megestrol acetate to help people with advanced small cell lung cancer who have lost weight and appetite. The goal is to see if the drug can improve their condition.

NCT07356037Not yet recruiting· Phase 3
Nanocrystalline megestrol acetate for liver cancer wasting

This trial tests a drug called nanocrystalline megestrol acetate to help people with advanced liver cancer who are losing weight and muscle mass. It's for those who have not yet had systemic therapy and are receiving other cancer treatments at the same time.

Chengdu, Sichuan
NCT06961188Not yet recruiting· Phase 3
Appetite and weight gain study for advanced lung cancer

This trial tests a new form of megestrol acetate (a medicine used to boost appetite and help with weight gain) in people with advanced lung cancer who are losing weight or at risk of weight loss. It aims to improve appetite and help you gain weight.

Wuhan, Hubei
NCT06793228Not yet recruiting· Phase 2
A trial for advanced small cell lung cancer with weight loss

This trial tests a combination of nanocrystalline megestrol (a medicine to improve appetite and weight) with standard chemotherapy and immunotherapy as a first treatment for people with extensive-stage small cell lung cancer who have lost weight or have early signs of cachexia (wasting syndrome). The goal is to see if this approach can help you feel better and live longer.

Luoyang, Henan
NCT07477808Not yet recruiting· Phase 3
Megestrol acetate for advanced lung cancer with weight loss

This trial tests whether a medicine called megestrol acetate can help improve appetite and weight in people with advanced lung cancer who are malnourished. It's for those who haven't had chemotherapy for their advanced cancer yet.

NCT07092137Not yet recruiting· Phase 2
Nano megestrol for appetite and weight loss in advanced lung cancer

This trial tests a nano form of megestrol acetate, a drug that may help improve appetite and reduce weight loss in people with advanced lung cancer who have already lost weight or have signs of inflammation. It's for those who have not yet had chemotherapy for advanced disease.

Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.